Castle Biosciences' DecisionDx-Melanoma Test Enhances Risk Prediction for Melanoma Management Castle Biosciences will showcase new insights on how its DecisionDx-Melanoma test better predicts risks in melanoma, enhancing patient management approaches at AAD 2026.

Castle Biosciences' DecisionDx-Melanoma Test Enhances Risk Prediction for Melanoma Management #USA #Denver #Castle_Biosciences #Melanoma_Test #DecisionDx-Melanoma

Innovative Merlin CP-GEP Test Boosts Melanoma Prognosis with New Findings A recent independent study in the Netherlands confirms the effectiveness of the Merlin CP-GEP Test for predicting melanoma prognosis in patients, enhancing personalized care.

Innovative Merlin CP-GEP Test Boosts Melanoma Prognosis with New Findings #Netherlands #Rotterdam #SkylineDx #Merlin_CP-GEP #Melanoma_Test